Principal Investigator
David Kerman
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20221164
Clinical Trial Summary
A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis.
Phase
TBD
Funding Agency/Sponsor
Intramural
Disease
Other
Contact Information
Study Contact
Niurka Colina
Phone Number
+1 (305) 2436405
Email
nxc610@miami.edu